Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for AIM ImmunoTech Inc. (AIM : AMEX)

• Company Description    AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases. The company's flagship products include Ampligen(R), Rintamod(R) and Alferon N Injection(R) which are in clinical stage. AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is based in Ocala, Florida. Number of Employees: 23

• Price / Volume Information    Yesterday's Closing Price: $1.13 Daily Weekly Monthly 20 Day Moving Average: 159,788 shares Shares Outstanding: 2.85 (millions) Market Capitalization: $3.22 (millions) Beta: 1.21 52 Week High: $10.38 52 Week Low: $0.03 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -23.13% -23.00% 12 Week -56.71% -57.40% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2117 SW HIGHWAY 484 - OCALA,FL 34473 USA ph: 352-448-7797 fax: 215-988-1739 aim@jtcir.com http://www.aimimmuno.com

• General Corporate Information    Officers Thomas K. Equels - Chief Executive Officer & President William Mitchell - Chairman of the Board Peter Rodino - Chief Operating Officer; General Counsel & Secreta Robert Dickey - Chief Financial Officer Ted D. Kellner - Director Peer Information AIM ImmunoTech Inc. (GSAC) AIM ImmunoTech Inc. (CASI) AIM ImmunoTech Inc. (ALCD.) AIM ImmunoTech Inc. (OMNN) AIM ImmunoTech Inc. (CGPI.) AIM ImmunoTech Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 00901B303 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/26/26 Share - Related Items Shares Outstanding: 2.85 Most Recent Split Date: 6.00 (0.01:1) Beta: 1.21 Market Capitalization: $3.22 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.33 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 28.79 EPS Growth vs. Year Ago Period: 94.67% vs. Previous Quarter: 91.30% Sales Growth vs. Year Ago Period: -25.71% vs. Previous Quarter: 4.00% ROE 12/31/25 - - 09/30/25 - - 06/30/25 - - ROA 12/31/25 - - 09/30/25 - -214.60 06/30/25 - -198.52 Current Ratio 12/31/25 - - 09/30/25 - 0.64 06/30/25 - 0.10 Quick Ratio 12/31/25 - - 09/30/25 - 0.64 06/30/25 - 0.10 Operating Margin 12/31/25 - - 09/30/25 - -11,725.89 06/30/25 - -13,360.33 Net Margin 12/31/25 - - 09/30/25 - -14,062.50 06/30/25 - -13,360.33 Pre-Tax Margin 12/31/25 - - 09/30/25 - -14,062.50 06/30/25 - -13,360.33 Book Value 12/31/25 - - 09/30/25 - -2.20 06/30/25 - -8.57 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - -

Powered by Zacks Investment Research ©